It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
WhiteAlice
reply to post by Danbones
I honestly think that society spends a little too much time trying to homogenize everyone within it. Sure there are cases where a differential brain can create an actual problem and necessitates assistance. Did you ever watch that Ted Talk with Temple Grandin? She pretty much talks about why difference is actually needed.
candlestick
WhiteAlice
reply to post by Danbones
I honestly think that society spends a little too much time trying to homogenize everyone within it. Sure there are cases where a differential brain can create an actual problem and necessitates assistance. Did you ever watch that Ted Talk with Temple Grandin? She pretty much talks about why difference is actually needed.
Elites don't need a diversification society.Too hard to control.
originally posted by: thellory
I'm sorry but if you believe that vaccines don't help us or they cause autism.. you need to leave the gene pool.
NJ Mumps Victims Were Vaccinated
www.fda.gov...
All subjects in the NCKP efficacy trial were followed for specified adverse events.
Hospitalizations within 60 days of study vaccines, emergency room visits within 30 days, and
outpatient clinic visits within 30 days of each vaccine dose were recorded.
Rates of outpatient clinic visits for diagnoses of interest (i.e. seizures, allergic reactions, including hives, wheezing,
shortness of breath and asthma) were also assessed and provided in the PLA.
Rates of hospitalizations for febrile seizures within 30 days and 60 days of a study vaccine dose
were significantly greater in the 7VPnC group than in the MnCC group for the first 3 dose series
and across all doses, when given concurrently with whole cell pertussis containing vaccine. .
11 Rate of hospitalization for asthma within 60 days of a vaccine dose was significantly greater in
the 7VPnC during the 3 first dose series when administered concurrently with acellular pertussis
containing concomitant vaccines.
Rate of hospitalization for gastroenteritis within 14 days of a vaccine dose was significantly
greater in the 7VPnC group, regardless of concomitant pertussis vaccine.
In the NCKP efficacy study, information about seizure events was collected through
hospitalizations, emergency room visits, and clinic databases.
Seizure events might also be detected among the actively monitored subset, as "convulsions" were listed among the solicited
events. Seizures were also listed among the reasons for study termination.
FDA asked Wyeth-Lederle to provide an integrated summary of all seizure events, in which
discrete events would be counted only once, and acute events would be distinguished from
follow-up visits or an ongoing seizure disorder by means of chart review.
Other potential sources of information, including spontaneous reports from clinic study nurses (not in the original PLA)
were also reviewed. Using all data sources, the number of subjects that experienced acute
seizure events occurring within 3, 14, and 30 days of a study vaccine dose were assessed (Table 4).
T a bl e 4 118 -08 : Nurnbero f S b ° u 'Jec ts WI °th A t S . eu e elzure Events
Period after Receipt of Number of Children Experiencing Acute Seizure Event
Study Vaccine Dose
..............7VPnC MnCC
Within 30 days 32 41
Within 14 days 21 21
Within 3 days ....8 4
From October 18, 1999 submission to PLA.
Of the 8 recipients of 7VPnC with acute seizure events within 3 days of inoculation, 7 were
described as febrile seizures, and 7 had received a whole cell pertussis containing vaccine
concurrently with. study vaccines.
The comparison between vaccine groups of rates of seizures occurring within 3 days of a vaccine dose was not statistically significant. These reports of febrile seizures likely represent a fairly complete assessment of febrile seizure episodes in the study, as several ascertainment modalities were used.
Based on 55,000 doses administered in the efficacy trial, the febrile seizure rate was approximately 1 per 7000 doses. This is substantially
less frequent than the historical rate of 1 per 1750 reported for whole cell pertussis vaccines (AAP Redbook 2000), despite concurrent administration of Prevnar with DTwP for the greater part of the study.
The safety evaluation was complicated by the background of concurrent immunizations and by
the use of an investigational vaccine in the control arm.
Thus, FDA reviewers sought to assure that the safety of Prevnar was further evaluated by comparing rates of selected uncommon and
rare adverse event rates to historical rates for events such as sudden infant death syndrome
web.archive.org...://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM238146.pdf
www.fda.gov...
We note that there was one case of autism within three days following the fourth dose of Pentacel (49401_addnl_safetyanalyses.pdf, page 260). This event was not included in the tables of serious adverse events.
a. The protocol-specified definition of serious adverse events included events that resulted in persistent or significant disability/incapacity. Please explain why autism was not classified as a serious adverse event.
b. Please provide a summary of all adverse events that resulted in a persistent or significant disability/incapacity but were not classified as serious adverse events.
c. Please provide a case narrative for the case of autism.